Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PSB-21644
- Development stage
- Unknown
- Lead developer
- University of Bonn
01
Overview
PSB-21644: sourced facts only. name: "In contrast, the related N-(2-(benzyloxy)phenyl)quinoline-6-carboxamide (4a, PSB-21644) behaved as a potent partial CB2 receptor agonist, showing nanomolar potency in β-arrestin-2 recruitment assays (EC50 0.0371 µM, Emax 65 %)." [PMID:41173052]; target: "In contrast, the related N-(2-(benzyloxy)phenyl)quinoline-6-carboxamide (4a, PSB-21644) behaved as a potent partial CB2 receptor agonist, showing nanomolar potency in β-arrestin-2 recruitment assays (EC50 0.0371 µM, Emax 65 %)." [PMID:41173052]; developer: "Pharmaceutical Institute, Department of Pharmaceutical & Medicinal Chemistry, University of Bonn, An der Immenburg 4, D-53121 Bonn, Germany." [PMID:41173052]
02
Targets
CB (Cannabinoid receptors)
Beyond the preview
Go deeper on PSB-21644.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PSB-21644.